Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call ...

The drugmaker shared limited early results from a Metsera obesity treatment as investors weigh its $10 billion acquisition and declining Covid sales.

With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, "Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

Pfizer PFE reported fourth-quarter 2025 adjusted earnings per share of 66 cents, which comprehensively beat the Zacks ...

Pharmaceutical giant Pfizer (PFE) released its fourth quarter earnings results that topped Wall Street's expectations on its ...

Pfizer (PFE) stock falls as the company posts mid-stage trial data for obesity therapy PF’3944. Read more here.

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Good day, everyone, and welcome to Pfizer's Fourth Quarter 2025 Earnings Conference Call. Today's call is being recorded. At ...

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.